Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286582 | 0.91 | CTSK (0.37) | CTSKMAPTADORA2AADORA2BAGTR1 | |
| SCHEMBL3285814 | 0.78 | CTSK (0.60) | CTSKADORA2AADORA2BCNR2 | |
| SCHEMBL9392791 | 0.66 | ADORA2B (0.58) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL17835296 | 0.63 | MAPT (0.42) | MAPTCYP1A2 | |
| SCHEMBL25278231 | 0.61 | CTSK (0.48) | CTSKMAPTCNR2 | |
| SCHEMBL13625665 | 0.61 | ACHE (0.40) | CYP1A2 | |
| SCHEMBL6047958 | 0.59 | CYP1A2 (0.50) | MAPTOPRK1CYP1A2 | |
| SCHEMBL9190697 | 0.59 | SIGMAR1 (0.70) | MAPTCYP1A2 | |
| SCHEMBL10579794 | 0.59 | CYP1A2 (0.68) | CYP1A2 | |
| SCHEMBL5614191 | 0.59 | SIGMAR1 (0.70) | MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | CTSK 4406/4885MAPT 4269/4885ADORA2A 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.